08:48:53 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-11-13 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-05-16 Extra Bolagsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-05-02 X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-05-08 X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-09 X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 Årsstämma 2022
2022-04-21 Bokslutskommuniké 2021
2021-09-30 Extra Bolagsstämma 2021
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-10 X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 Årsstämma 2021
2021-04-20 Bokslutskommuniké 2020
2020-06-26 Årsstämma 2020
2020-06-01 Bokslutskommuniké 2019
2019-02-07 Split LIFE 4:1
2018-12-11 Extra Bolagsstämma 2018


ListaEuronext Growth Oslo
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2024-06-10 08:25:00

Bergen, Norway, June 10th, 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the company have improved the read-out distance from sensor to the read-out device.

Reference is made to previous communications in the Q1 reporting regarding the need to improve the read-out distance to start the pending longevity study. This longevity study on dogs will be performed at the Norwegian University of Life Sciences (NMBU), located in Ås, close to Oslo.

In the longevity study, the company will introduce wireless communication between the implanted sensor and the outside read-out device. The Lifecare team has been working with external specialized consultants to improve the signal read-out distance to meet requirements, as defined by Lifecare.

The reports from factory acceptance tests conducted by Lifecare confirms satisfactory read-out distance. This conclusion being important for two reasons. Firstly, this means that Lifecare now are ready to start the longevity study in dogs, only pending final internal in-vitro sensor quality control. Secondly, the confirmed read-out distance meets Lifecare’s requirements from a product development perspective, additional improvements for distance read-out are not expected to be necessary going forward. Given that the quality in-vitro testing goes as planned, the longevity study can start at NMBU in mid-June.

- Integration of wireless communication in our state-of-the-art sensor is a sensitive matter, although solvable. Our engineers and scientist have improved the read-out distance. For us, this was a question of when, not if, we could meet the defined requirements. Now we can look forward to starting the longevity study in June. Furthermore, given good results from the longevity study and the ongoing progress towards automated production, the confirmed read-out distance is an important progress towards product readiness in the veterinary market, says CEO Joacim Holter at Lifecare.

Managing Director, Jo Amundstad of the subsidiary Lifecare Veterinary, will be responsible for carrying out the study in collaboration with NMBU. - We are fortunate to have with us some of the leading experts in internal medicine at NMBU to take part in the studies. Among these, PhD candidate Sivert Nerhagen has already been employed. He has taken part in the important preparations for the longevity study, says Amundstad. He points out that the recruitment process of patients for the study also is well under way.